CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer
Condition: Squamous Cell Carcinoma of the Oral Cavity Interventions: Biological: Nivolumab, Surgery, Radiotherapy; Biological: Nivolumab, Surgery, Chemoradiotherapy Sponsors: The Clatterbridge Cancer Centre NHS Foundation Trust; University of Liverpool; Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials